Twist Bioscience (TWST) analyst forecast and price target
Analyst forecast
Consensus of 10 analyst ratings
Based on 9 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Canaccord Genuity | Maintained | Buy | $205.00 from $120.00 | Oct 12, 2026 |
| Jefferies | Initiated Coverage | Hold | $150.00 | Oct 8, 2026 |
| Barclays | Maintained | Overweight | $215.00 from $112.00 | Oct 7, 2026 |
| Guggenheim | Maintained | Buy | $212.00 from $107.00 | Oct 1, 2026 |
| Leerink Partners | Maintained | Outperform | $190.00 from $160.00 | Sep 29, 2026 |
| BWS Financial | Maintained | Sell | $45.00 | Sep 18, 2026 |
| Leerink Partners | Maintained | Outperform | $160.00 from $120.00 | Sep 17, 2026 |
| UBS | Initiated Coverage | Neutral | $144.00 | Sep 9, 2026 |
| BWS Financial | Initiated Coverage | Sell | $45.00 | Sep 9, 2026 |
| Piper Sandler | Maintained | Overweight | $115.00 from $85.00 | Aug 5, 2026 |
| Baird | Maintained | Outperform | $115.00 from $113.00 | Aug 4, 2026 |
| Canaccord Genuity | Maintained | Buy | $120.00 from $90.00 | Jul 14, 2026 |
| Evercore ISI Group | Downgraded | Outperform → In-Line | $102.00 from $66.00 | Jul 6, 2026 |
| Guggenheim | Maintained | Buy | $107.00 from $60.00 | Jun 29, 2026 |
| Barclays | Maintained | Overweight | $95.00 from $65.00 | Jun 24, 2026 |
| TD Cowen | Maintained | Buy | $89.00 from $68.00 | Jun 15, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $90.00 | Jun 15, 2026 |
| Piper Sandler | Initiated Coverage | Overweight | $85.00 | Jun 11, 2026 |
| Guggenheim | Maintained | Buy | $60.00 from $55.00 | May 5, 2026 |
| Barclays | Maintained | Overweight | $65.00 from $55.00 | May 5, 2026 |
Frequently asked questions
What is the price target for TWST stock?
The average 12-month analyst price target for Twist Bioscience (TWST) is $154.56, with a high estimate of $215.00 and a low of $45.00, across 9 analysts.
Is TWST a buy, sell, or hold?
Analysts covering Twist Bioscience currently average a Buy rating: 9 buy, 1 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for TWST?
The average price target of $154.56 implies 1.78% upside from the last price of $151.86.
What is the latest analyst rating on TWST?
On Oct 12, 2026, Canaccord Genuity maintained Twist Bioscience at Buy with a price target of $205.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.